Improved US prospects, domestic outlook to drive Sun Pharma's earnings

The Sun Pharma stock hit its 52-week high earlier this week on strong domestic growth expectations and improved outlook for the US market, following the clearance for its Halol manufacturing plant in Gujarat. The stock is up almost 20 per cent in less than a month after the company posted better-than-expected June-quarter earnings. Analysts at Credit Suisse have upgraded the stock recently as they believe upside from an acne treatment drug could lead to a re-rating. The key near-term trigger is the company's specialty pipeline. In addition to the recent launch of Yonsa (anti-cancer d.....

Key stories on are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.